CD8A and neoplasm: engineered an IL-10-Fc fusion protein with a longer half-life than previous IL-10-based drugs that directly and potently increased the proliferation and effector function of terminally exhausted tumor-infiltrating CD8+ T cells by enhancing oxidative phosphorylation, a process that was triggered independent of exhausted progenitor T cells (Figure 5C).